Growth Hormone

CJC-1295 with DAC

CJC-1295 DAC · Modified GRF(1-29) with DAC

Tetrasubstituted GHRH(1-29) with an albumin-binding DAC. Teichman 2006 (PMID 16352683) is healthy-adult GH/IGF-1 PK. Not somatropin, not Mod GRF, not a weekly HGH replacement. No FDA finished-product label.

Not FDA-approved - research chemicalWADA (S2) - prohibited in sport at all times

Reviewed by CalcMyPeptide Editorial Team

·Last updated: August 2026·Evidence: Moderate·2 peer-reviewed citations

Typical research dose

1000-2000 mcg/week

Frequency

1-2× weekly

Half-life

5.8 - 8.1 days

Common vials

2 mg / 5 mg

CAS

863288-34-0

Molecular weight

3647.28 g/mol

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Muscle / recomp4.5/10
Teichman 2006 (PMID 16352683) is small-human GH/IGF-1 PK, not a hypertrophy RCT. Ceiling 6.5 for small human; haircut for no label and research-chem identity.
Recovery & sleep4/10
Sleep/recovery language is GH physiology plus community use. Not a sleep RCT.

Compound card

Sequence: Tetrasubstituted GHRH(1-29) + maleimidopropionyl DAC
Class: Long-acting GHRH analog (albumin-bound; not FDA-approved)
Formula: C152H252N44O42S
Status: Not FDA-approved · research use

Dose it

2 mg + 2 mL BAC water → 1 mg/mL · 1000 mcg ≈ 100 units (U-100)

Open in calculator

How it works

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). The DAC modification binds to albumin in the bloodstream, extending the half-life from 30 minutes to 5.8-8.1 days. This creates sustained, elevated growth hormone release from pituitary somatotroph cells.

Teichman 2006 (JCEM, PMID 16352683) is the healthy-adult PK paper. Ionescu and Frohman (JCEM, PMID 17018654) showed pulsatility persisted after a single injection, with a marked rise in trough GH. That is not a flat GH infusion and it is not a 2–10× hypertrophy claim. ConjuChem’s later HIV-VAT program did not become a US label.

Source: PMID: 16352683

Background & History

CJC-1295 with DAC is ConjuChem’s albumin-binding GHRH analog. Teichman 2006 (PMID 16352683) is the healthy-adult JCEM paper. Walker 2006 is a sermorelin editorial, not this molecule. Ionescu 2006 (PMID 17018654) is related DAC work. Research cakes are not that trial lot.

Research Use Cases

✓DAC vs Mod GRF identity (do not reuse Teichman as no-DAC PK)
✓Once-weekly GHRH analog folklore vs a 2–3×/day pulse analog
✓Not a somatopause drug and not somatropin

Dosing

Phase	Dose	Frequency	Notes
Standard Protocol	1,000 - 2,000 mcg (1-2 mg)	once or twice weekly	Lower dose (1mg) for general anti-aging; higher (2mg) for accelerated GH/IGF-1 elevation.

Administration

Route / form

Subcutaneous injection

Timing

Any time of day. Due to long half-life, timing is not critical. Evening preferred by many to align with natural GH rhythms.

Empty stomach?

No - Food timing is not critical.

Timeline

Week 1-2

IGF-1 begins rising. Improved sleep quality often noticed first.

Month 1-2

Recovery improvements, modest body composition shifts (increased lean mass, reduced fat).

Month 3+

Peak IGF-1 elevation and compounding body composition benefits.

Who it is for

Anti-Aging / Longevity

Moderate

Sustained GH/IGF-1 elevation without daily injections - favorable for long-term protocols.

Body Composition

Moderate

Lean mass support and fat reduction with weekly dosing convenience.

Reconstitution

Vial	Water	Concentration	Example dose
2 mg lyophilized	2.0 mL BAC	1 mg/mL	1 mg = 1.0 mL = 100 units on a U-100.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Research peptide - not FDA-approved. May cause water retention, numbness/tingling in extremities, and headache. Should not be used by individuals with active cancer due to GH/IGF-1 elevation. Growth hormone secretagogues may affect blood glucose levels.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Prohibited (S2)

Competitive athletes subject to anti-doping controls should not use CJC-1295 with DAC.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

Ionescu/Frohman is PMID 17018654, not 16822818. Teichman healthy-adult PK is PMID 16352683.
“2–10× GH” is not the paper. Ionescu reported a large trough-GH rise with preserved pulsatility, not a bodybuilding multiplier.
Phase 2 HIV-VAT work was discontinued. No FDA finished-product label.
Do not file Mod GRF (no DAC) as this molecule. Different PK, different CAS.

Verdict

CJC-1295 with DAC is the albumin-binding GHRH analog from ConjuChem’s program. Teichman/Ionescu measured GH and IGF-1 in healthy adults. It is not somatropin, not weekly “HGH in a peptide,” and not Mod GRF. A 2 mg cake is not that trial material.

Interactions & Contraindications

GH-class glucose and IGF-1 watching. Active malignancy is a hard no. Do not treat Teichman percents as a 2 mg research cake.

Synergies & Common Stacks

+ Ipamorelin →

GHRH receptor plus GHS-R1a is two receptors. Sustained DAC exposure plus a pulse peptide is a clinic habit, not a labeled 2–5× endpoint.

CJC-1295 with DAC vs. CJC-1295 (No DAC)

Canonical comparison: CJC-1295 with DAC vs CJC-1295 (No DAC)

Attribute	CJC-1295 with DAC	CJC-1295 (No DAC)
DAC Modification	Drug Affinity Complex (DAC) attached	No DAC - plain modified GHRH
Half-Life	5.8–8.1 days (once or twice weekly)	~30 minutes (1–3× daily required)
GH Pattern	Sustained non-pulsatile bleed	Sharp, natural-mimicking pulses
Stacking	Typically used solo or with GHRP	Best paired with Ipamorelin (gold standard)
Convenience	Maximum - 1–2×/week dosing	Requires 1–3 daily injections
IGF-1 Concerns	Higher IGF-1 elevation (sustained)	More physiological IGF-1 profile

Verdict: CJC-1295 DAC wins for convenience (twice-weekly dosing); CJC-1295 No DAC wins for physiological GH pulse preservation. The No DAC + Ipamorelin stack is preferred by most protocols for mimicking natural GH rhythms and avoiding chronically elevated IGF-1.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?▼

CJC-1295 with DAC has a half-life of 5.8-8.1 days (dosed 1-2× weekly), while CJC-1295 without DAC (Mod GRF 1-29) has a 30-minute half-life (dosed 1-3× daily). The DAC version provides sustained GH elevation; the non-DAC version creates sharper, more natural GH pulses.

How do I dose CJC-1295 DAC?▼

Standard dose: 1,000-2,000 mcg (1-2 mg) once or twice weekly via subcutaneous injection. For a 2 mg vial with 2 mL BAC water, each 10 units on a 100-unit syringe delivers 100 mcg.

When should I inject CJC-1295 DAC?▼

CJC-1295 DAC can be injected at any time due to its long half-life. Many users prefer evening injection to align with natural nighttime GH pulses, but timing is less critical than with the non-DAC version.

References

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology & Metabolism (2006). PMID: 16352683
Ionescu M, Frohman LA “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” Journal of Clinical Endocrinology & Metabolism (2006). PMID: 17018654

📚 Related Articles

Peptide Half-Life Explained: Why It Matters for Your Dosing Schedule

6 min read • Education

How to Reconstitute Peptides: A Complete Step-by-Step Guide (2026)

12 min read • Guide

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →

← Back to Peptide Library